Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study on Immune Checkpoint Inhibitors and Radioembolisation for Previously Untreated Metastatic Hepatocellular Carcinoma

NCT05809869 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT05809869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05809869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study on Immune Checkpoint Inhibitors and Radioembolisation for Previously Untreated Metastatic Hepatocellular Carcinoma
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Unknown status
Start date
February 15, 2023
Completion date
June 30, 2026
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma